tHEORetically Speaking
Menu Close
  • Home
  • Guest Bloggers
  • About Us
  • HealthEconomics.Com
  • HE Jobs Portal

Caitlin Rothermel

Posted on March 7, 2013 by Patti Peeples, R.Ph., Ph.D.

What do you think?  Should PROs be included in composite endpoints along with more traditional clinical measures?  Read Cardiovascular Disease and Patient-reported Outcomes – Can Composite Endpoints Work? by Caitlin Rothermel and weigh in!

Share this...
Share on Facebook
Facebook
Tweet about this on Twitter
Twitter
Share on LinkedIn
Linkedin
Email this to someone
email
Print this page
Print
Guest Bloggers cardiovascular disease, clinical trials, composite endpoints, Evidence-based medicine, PROs

Post navigation

Shock Treatment
Satisfaction Goes Social

About the HealthEconomics.Com Blog:

Insights, observations, executive interviews, critical analysis, and new research for health economics, outcomes research, real-world evidence, and market access community. We welcome guest bloggers.

Subscribe for updates

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 70 other subscribers

Recent Posts

  • Revealing the Unknown: How the COVID Active Research Experience (CARE) Registry is Enhancing Community Health
  • COVID-19 and Racial/Ethnic Disparities in Health
  • The 5 Numbers That Will Define Healthcare Value in 2021
  • Size Doesn’t Matter: A Small Biotech Plays Big with Payer Engagement
  • How Health Economics and Outcomes Researchers Can Help Defeat COVID-19

Dr. Peeples Tweets!

HealthEconomics.Com | A Scientist.com CompanyFollow

HealthEconomics.Com | A Scientist.com Company
www_healtheconHealthEconomics.Com | A Scientist.com Company@www_healthecon·
7h

Reference Pricing Could Negatively Affect Vulnerable Populations http://ow.ly/mpXB50DJbgo #HEOR #data #research #value #value-assessment

Reply on Twitter 1364741944266674181Retweet on Twitter 1364741944266674181Like on Twitter 13647419442666741811Twitter 1364741944266674181
www_healtheconHealthEconomics.Com | A Scientist.com Company@www_healthecon·
8h

Webinar on Providing Meaningful Price Transparency Information http://ow.ly/i5PW50DJaLD #HEOR #data #healthcare #patient-centered

Reply on Twitter 1364726849335660546Retweet on Twitter 1364726849335660546Like on Twitter 1364726849335660546Twitter 1364726849335660546
www_healtheconHealthEconomics.Com | A Scientist.com Company@www_healthecon·
9h

Using RWE to Make Cost Decisions: A New Report http://ow.ly/d2Eu50DJ9Uo #HEOR #RWD #RWE #data #research #pharma @icer_review

Reply on Twitter 1364711752437497861Retweet on Twitter 1364711752437497861Like on Twitter 13647117524374978612Twitter 1364711752437497861
Load More...

Archives

Visit our website, HealthEconomics.Com, top ranked by Google for news, jobs and resources in healthcare value, market access and more. Read our privacy policy here.
© 2021 tHEORetically Speaking. All rights reserved.
Hiero by aThemes